World Market Media's  Instablog

World Market Media
Send Message
GLX - The Global Listing Exchange is a social finance portal to the world’s capital markets. GLX organizes all of the necessary fundamental information and bridges the world’s investment communities giving every member the power to connect, transact and profit.
My company:
World Market Media
My blog:
Straight Talk On SmallCap
  • Neurologix, Inc. $35M (MarketCap) Releases Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease  0 comments
    Jun 22, 2010 2:42 PM | about stocks: NRGX
    Parkinson’s disease is a progressive and debilitating neurodegenerative disorder that arises from the gradual deterioration of nerve cells in the brain. It affects the control of bodily movement and is characterized by four principal symptoms: limb tremor, limb rigidity, bradykinesia (slowness of movement) and postural instability (trouble with balance). According to the National Parkinson Foundation, 1 million Americans currently have PD, and an estimated 50,000 to 60,000 new cases are diagnosed each year in the United States. Unfortunately, many patients develop complications from dopaminergic interventions, the standard therapy/ treatment used for Parkinson’s. Consequently, the need for a new type of treatment is in high demand. Today, Neurologix, Inc. (OTCBB: NRGX) announced positive results in a Phase 2 trial of its investigational gene therapy for advanced Parkinson’s disease (PD), NLX-P101. The company is currently trading at $1.25, up $0.50 or 66.67% following this announcement.

    Neurologix, Inc. is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of gene transfer therapies for serious disorders of the brain and CNS.  Its technology is the only gene therapy strategy currently in development which bypasses the dopamine system that patients frequently develop complications from. Neurologix's investigational AAV (adeno-associated virus) vector gene therapy, NLX-P101, is a novel, non-dopaminergic approach that uses an inhibitory gene to selectively alter the neural circuitry affected in PD and, thereby, normalize brain physiology. The Phase 2 trial results demonstrated a positive safety profile for NLX-P101, with no serious adverse events related to the gene therapy or surgical procedure reported. Patients enrolled in the trial had moderate to advanced PD and were not adequately responsive to current therapies.

    "Based on this data, we are confident that NLX-P101 has great potential to advance the treatment paradigm for Parkinson's patients, and to eventually offer an important, new therapy for patients with this debilitating disease.  The study investigators continue to further evaluate the detailed data and we look forward to its publication or presentation," said Clark A. Johnson, President and Chief Executive Officer of the Company. "Today's news is also important validation for our ongoing development of other technologies for neurological and psychiatric diseases, including our advanced pre-clinical program in epilepsy. Given these results, we would look to pursue a strategic transaction which will maximize value for the Company."


    To view this article at World Market Media click on the link below:

    Disclosure: no positions
    Stocks: NRGX
Back To World Market Media's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.